We are pleased to announce that STA Pharmaceutical Co., Ltd. (STA), a WuXi subsidiary, has signed a supply agreement with the oncology-focused biopharmaceutical company, TESARO, Inc. for certain starting and intermediate materials for ZEJULA™ (niraparib).

Under the five-year agreement, STA will provide supply of certain starting and intermediate materials for the recently launched ZEJULA – an orally active and potent poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of ovarian cancer. ZEJULA was approved for epithelial ovarian, fallopian tube or primary peritoneal cancer by the U.S. Food and Drug Administration (FDA) on March 27th 2017, and is now available to patients in the USA.

STA – a leading open-access capability and technology platform for small molecule pharmaceutical development and manufacturing – is committed to helping its partners develop and commercialize innovative breakthrough drugs like ZEJULA via our state-of-the-art enabling platform.

Related Links

Official Press Release

WuXi AppTec’s STA Subsidiary Passed Third U.S. FDA Inspection